Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 2/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.47 |
| ▸ | CALCR | P30988 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.45 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.45 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | TFPI | P10646 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13311924 | 0.80 | PIN1 (0.49) | PIN1RAMP3CALCROPRD1KDM1A | |
| SCHEMBL14524261 | 0.79 | PIN1 (0.47) | PIN1RAMP3CALCROPRD1KDM1A | |
| SCHEMBL3805702 | 0.78 | RAMP3 (0.55) | PIN1RAMP3CALCRCXCR4TFPI | |
| SCHEMBL29980543 | 0.77 | EPHA2 (0.57) | EPHA2OPRD1KDM1AMAOBKDM5A | |
| SCHEMBL29980542 | 0.77 | EPHA2 (0.59) | EPHA2OPRD1KDM1AMAOBKDM5A | |
| Angiotensin Amide SCHEMBL4448793 | 0.75 | AGTR2 (0.63) | RAMP3CALCRTFPI | |
| SCHEMBL13311821 | 0.75 | EPHA2 (0.62) | EPHA2OPRD1KDM1AMAOBKDM5A | |
| SCHEMBL29980254 | 0.75 | KDM1A (0.63) | EPHA2RAMP3CALCRCXCR4KDM1A | |
| SCHEMBL7113668 | 0.74 | FOLH1 (0.50) | PIN1RAMP3CALCR | |
| SCHEMBL15788093 | 0.74 | LCK (0.48) | AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078094-A1 | Guanidinium delivery carriers | NITTO DENKO CORPORATION (JP) | 2007-04-05 | — | — | US | disclosed |
| US-20070078094-A1 | Guanidinium delivery carriers | NITTO DENKO CORPORATION (JP) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078094-A1 | Guanidinium delivery carriers | SLC2A9, SLC29A2, SLC2A4 | EPHA2 611/4885AKT1 3739/4885PIN1 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.